Hold Rating on XOMA's Acquisition of LAVA Therapeutics: Valuation and Risks AssessedValuation and Risks. We maintain our Neutral rating on LVTX and lower our price target to $1.24 per share, from $1.50. We derive our price target based on the maximal cash value of the XOMA acquisition. (1) clinical; (2) regulatory; (3) commercial; (4) competition; (5) collaboration; (6) manufacturing, and (7) dilution.